Mitsubishi UFJ Trust & Banking Corp decreased its stake in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 4.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,183 shares of the company’s stock after selling 1,394 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.07% of Taro Pharmaceutical Industries worth $3,158,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Anchor Capital Advisors LLC raised its stake in Taro Pharmaceutical Industries by 0.4% during the second quarter. Anchor Capital Advisors LLC now owns 20,733 shares of the company’s stock valued at $2,323,000 after buying an additional 77 shares during the last quarter. Bank of Montreal Can raised its stake in Taro Pharmaceutical Industries by 7.5% during the second quarter. Bank of Montreal Can now owns 2,128 shares of the company’s stock valued at $238,000 after buying an additional 149 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Taro Pharmaceutical Industries by 7.4% during the second quarter. Russell Investments Group Ltd. now owns 2,257 shares of the company’s stock valued at $253,000 after buying an additional 156 shares during the last quarter. Creative Planning raised its stake in Taro Pharmaceutical Industries by 3.8% during the second quarter. Creative Planning now owns 7,186 shares of the company’s stock valued at $805,000 after buying an additional 265 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in Taro Pharmaceutical Industries by 4.7% during the second quarter. Legal & General Group Plc now owns 8,318 shares of the company’s stock valued at $932,000 after buying an additional 370 shares during the last quarter. Institutional investors and hedge funds own 14.24% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Mitsubishi UFJ Trust & Banking Corp Sells 1,394 Shares of Taro Pharmaceutical Industries Ltd. (TARO)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/10/mitsubishi-ufj-trust-banking-corp-sells-1394-shares-of-taro-pharmaceutical-industries-ltd-taro.html.

A number of brokerages have issued reports on TARO. BidaskClub upgraded Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research note on Saturday. TheStreet cut Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a research note on Wednesday, August 9th. Finally, Credit Suisse Group cut Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a research note on Tuesday, May 23rd.

Taro Pharmaceutical Industries Ltd. (NYSE TARO) opened at 104.95 on Friday. The firm’s 50-day moving average price is $106.84 and its 200-day moving average price is $112.23. Taro Pharmaceutical Industries Ltd. has a 52 week low of $92.28 and a 52 week high of $124.52. The stock has a market cap of $4.25 billion, a PE ratio of 10.69 and a beta of 0.65.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Stock Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.